| CAS No. | 1019000-64-6 |
| Chemical Name | PEG2000C-DMG |
| Synonyms | Not available |
| SMILES | CCCCCCCCCCCCCCOCC(OCCCCCCCCCCCCCC)COC(=O)NCCCO{-}CC{+n}OC |
| Formula | C36H73NO5(C2H4O)N |
| M.Wt | Not available |
| Purity | >98% |
| Storage | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Shipping condition | Ships from Shanghai; packaging confirmed at order. |
| Publication | 1. Hobo, W., Novobrantseva, T., Fredrix, H., et al. Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. Cancer Immunol. Immunother. 62(2), 285-297 (2013). |
| Product classification | PEGylated lipids |

PEG2000-C-DMG
Pack size & price
USDDescription & Application
PEG(2000)-C-DMG represents a PEGylated derivative synthesized from 1,2-dimyristoyl-sn-glycerol (1,2-DMG). This compound is instrumental in the formulation of lipid nanoparticles (LNPs), particularly when combined with other lipidic compounds, for the efficient delivery of small interfering RNA (siRNA). Specifically, LNPs incorporating PEG(2000)-C-DMG and encapsulating siRNA designed to target the genes responsible for encoding programmed cell death protein ligand 1 (PD-L1) and PD-L2 have demonstrated efficacy in reducing the expression levels of PD-L1 and PD-L2 in monocyte-derived dendritic cells. Furthermore, formulations that include PEG(2000)-C-DMG are being actively explored in the advancement of LNPs aimed at the delivery of siRNA-based vaccines, highlighting its critical role in the development of therapeutic and prophylactic strategies.
Solution Calculators
The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.
Need a different pack size or technical document?
Contact our team with the catalog number and requested quantity.
